TY - JOUR
T1 - A review of physical activity in pancreatic ductal adenocarcinoma
T2 - Epidemiology, intervention, animal models, and clinical trials
AU - Hsueh, Hsiang Yin
AU - Pita-Grisanti, Valentina
AU - Gumpper-Fedus, Kristyn
AU - Lahooti, Ali
AU - Chavez-Tomar, Myrriah
AU - Schadler, Keri
AU - Cruz-Monserrate, Zobeida
N1 - Publisher Copyright:
© 2021 IAP and EPC
PY - 2022/1
Y1 - 2022/1
N2 - Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer, and the increasing incidence of PDAC may be related to the prevalence of obesity. Physical activity (PA), a method known to mitigate obesity by increasing total energy expenditure, also modifies multiple cellular pathways associated with cancer hallmarks. Epidemiologic evidence has shown that PA can lower the risk of developing a variety of cancers, reduce some of the detrimental side effects of treatments, and improve patient's quality of life during cancer treatment. However, little is known about the pathways underlying the correlations observed between PA interventions and PDAC. Moreover, there is no standard dose of PA intervention that is ideal for PDAC prevention or as an adjuvant of cancer treatments. In this review, we summarize relevant literature showing how PDAC patients can benefit from PA, the potential of PA as an adjuvant treatment for PDAC, the studies using preclinical models of PDAC to study PA, and the clinical trials to date assessing the effects of PA in PDAC.
AB - Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer, and the increasing incidence of PDAC may be related to the prevalence of obesity. Physical activity (PA), a method known to mitigate obesity by increasing total energy expenditure, also modifies multiple cellular pathways associated with cancer hallmarks. Epidemiologic evidence has shown that PA can lower the risk of developing a variety of cancers, reduce some of the detrimental side effects of treatments, and improve patient's quality of life during cancer treatment. However, little is known about the pathways underlying the correlations observed between PA interventions and PDAC. Moreover, there is no standard dose of PA intervention that is ideal for PDAC prevention or as an adjuvant of cancer treatments. In this review, we summarize relevant literature showing how PDAC patients can benefit from PA, the potential of PA as an adjuvant treatment for PDAC, the studies using preclinical models of PDAC to study PA, and the clinical trials to date assessing the effects of PA in PDAC.
KW - Exercise
KW - Pancreatic cancer
KW - Pancreatic ductal adenocarcinoma
KW - Physical activity
KW - Translational research
UR - http://www.scopus.com/inward/record.url?scp=85118923773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118923773&partnerID=8YFLogxK
U2 - 10.1016/j.pan.2021.10.004
DO - 10.1016/j.pan.2021.10.004
M3 - Review article
C2 - 34750076
AN - SCOPUS:85118923773
SN - 1424-3903
VL - 22
SP - 98
EP - 111
JO - Pancreatology
JF - Pancreatology
IS - 1
ER -